LYRM7 Antibody

What is LYRM7 and why is it an important research target?

LYRM7 (also known as MZM1L) is a mitochondrial protein that functions as an essential assembly factor for respiratory chain complex III (CIII). It acts as a chaperone for the Rieske Fe-S protein (UQCRFS1), binding to this subunit within the mitochondrial matrix and stabilizing it prior to its translocation and insertion into the CIII dimeric intermediate within the mitochondrial inner membrane . Mutations in LYRM7 have been linked to severe mitochondrial disorders, including early-onset encephalopathy, lactic acidosis, and complex III deficiency, making it an important target for research into mitochondrial diseases .

The protein contains a LYR motif, which is found in several proteins involved in the biogenesis of iron-sulfur cluster containing structures. This motif appears to be critical for LYRM7's function in binding and stabilizing the Rieske Fe-S protein before its incorporation into complex III .

What applications are LYRM7 antibodies validated for?

Based on current commercial offerings and published research, LYRM7 antibodies have been validated for the following applications:

It's important to note that each antibody may have different optimal conditions, and validation should be performed in your specific experimental system .

How should I validate LYRM7 antibody specificity for my experimental system?

To ensure robust and reproducible results, validation of LYRM7 antibodies should include:

• Positive and negative controls: Use tissues/cells known to express LYRM7 (e.g., liver, kidney) as positive controls and LYRM7 knockout systems as negative controls .

• Molecular weight verification: LYRM7 has a calculated molecular weight of approximately 12 kDa. Confirm that your antibody detects a protein of this size by Western blot .

• Genetic validation:

  • siRNA knockdown of LYRM7

  • CRISPR/Cas9-mediated knockout

  • Overexpression of tagged LYRM7 (ensure tag doesn't interfere with epitope)

• Cross-reactivity testing: If working with non-human samples, verify species reactivity. LYRM7 is highly conserved between humans and yeast, allowing for functional complementation .

• Epitope mapping: Understand which region of LYRM7 your antibody recognizes. This is particularly important when studying specific domains like the LYR motif.

For advanced applications, you may also verify antibody specificity using mass spectrometry after immunoprecipitation experiments.

What are optimal sample preparation protocols for LYRM7 detection by Western blotting?

For effective detection of LYRM7 by Western blotting, consider the following protocol:

Cell/Tissue Lysis:

• Harvest cells or tissue samples and wash with PBS

• Lyse in buffer containing 1% n-Dodecyl β-D-maltoside (DDM), 140 mM NaCl in PBS, and protease inhibitor cocktail

• Incubate on ice for 30 minutes

• Clear lysate by centrifugation at 20,000×g for 30 minutes at 4°C

Mitochondrial Fraction (for better sensitivity):

• Isolate mitochondria using differential centrifugation

• Solubilize in 1% sodium deoxycholate, 100 mM Tris-Cl pH 8.1, 40 mM chloroacetamide and 10 mM TCEP

• Heat at 99°C for 5 minutes with shaking at 1500 rpm

• Sonicate for 15 minutes in a room temperature water bath

Gel Electrophoresis:

• Use 4-20% gradient gels for better resolution of the low molecular weight LYRM7 (12 kDa)

• Load appropriate positive controls (e.g., HDLM-2 cell lysate has been validated)

Transfer and Detection:

• Transfer to PVDF membrane (preferred over nitrocellulose for small proteins)

• Block with 5% non-fat milk or BSA

• Incubate with LYRM7 antibody at optimized dilution (typically 1:500-1:1000)

• For enhanced sensitivity, consider using HRP-conjugated secondary antibodies and enhanced chemiluminescence detection systems

When analyzing complex III assembly, blue native polyacrylamide gel electrophoresis (BN-PAGE) may be more informative than standard SDS-PAGE .

What are recommended immunostaining protocols for LYRM7 in fixed cells and tissues?

For Paraffin-Embedded Tissue Sections (IHC-P):

• Antigen Retrieval:

  • TE buffer pH 9.0 is the suggested primary method

  • Alternatively, citrate buffer pH 6.0 may be used

  • Heat treatment in pressure cooker: 20 minutes

• Blocking and Antibody Incubation:

  • Block with 10% normal serum in PBS for 1 hour at room temperature

  • Incubate with primary LYRM7 antibody at 1:20-1:200 dilution overnight at 4°C

  • Wash 3× with PBS-T

  • Incubate with appropriate HRP-conjugated secondary antibody for 1 hour at room temperature

  • Develop with DAB substrate

  • Counterstain with hematoxylin, dehydrate, and mount

For Immunofluorescence in Cultured Cells (IF/ICC):

• Fixation and Permeabilization:

  • Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.2% Triton X-100 in PBS for 10 minutes

  • For mitochondrial studies, consider co-staining with MitoTracker before fixation

• Immunostaining:

  • Block with 5% BSA in PBS for 1 hour

  • Incubate with LYRM7 antibody at 1:10-1:100 dilution overnight at 4°C

  • Wash 3× with PBS

  • Incubate with fluorophore-conjugated secondary antibody for 1 hour at room temperature

  • Counterstain nucleus with DAPI

  • Mount with anti-fade mounting medium

HepG2 cells have been validated as positive controls for LYRM7 immunofluorescence staining .

How can I optimize LYRM7 antibody performance in problematic samples?

When encountering difficulties with LYRM7 detection, consider these optimization strategies:

• Low Signal Issues:

  • Increase antibody concentration

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use signal enhancement systems (biotin-streptavidin, tyramide signal amplification)

  • Optimize antigen retrieval conditions (try both acidic and basic buffers)

  • Use fresh samples to minimize degradation

• High Background Issues:

  • Increase blocking time and concentration (try 5-10% BSA or normal serum)

  • Add 0.1% Tween-20 to antibody dilution buffers

  • Use more stringent washing steps (increase number and duration)

  • Try a different secondary antibody

  • Pre-adsorb antibodies with tissue powder

• Mitochondrial Protein-Specific Challenges:

  • Ensure gentle lysis conditions to preserve mitochondrial integrity

  • Consider using mitochondrial isolation before analysis

  • When working with blue native PAGE, handle samples at 4°C throughout

  • Add detergents suitable for mitochondrial membrane proteins (e.g., digitonin for gentler extraction, DDM for more thorough extraction)

• Cross-Reactivity Issues:

  • Perform peptide competition assays to verify specificity

  • Try antibodies targeting different epitopes of LYRM7

  • Use LYRM7 knockout samples as negative controls

How can I use LYRM7 antibodies to study complex III assembly and pathology?

LYRM7 antibodies can be powerful tools for investigating complex III assembly mechanisms and related pathologies:

• Co-immunoprecipitation Studies:

  • Use anti-LYRM7 antibodies to pull down protein complexes

  • Western blot for interaction partners (especially UQCRFS1/Rieske protein)

  • Protocol example: Lyse cells in PBS with 140 mM NaCl, 1% DDM and protease inhibitor cocktail; incubate with anti-LYRM7 antibody and protein G-Sepharose beads

• Analysis of Assembly Intermediates:

  • Blue native PAGE followed by Western blotting to identify complex III assembly intermediates

  • Compare LYRM7 mutant cells with wild-type to identify accumulated assembly intermediates

  • Sequential immunoblotting for LYRM7 and other complex III components can reveal assembly progression

• Submitochondrial Localization:

  • Use differential centrifugation to separate mitochondrial compartments

  • Immunoblot fractions to determine LYRM7 distribution

  • Compare with known markers for mitochondrial matrix, inner membrane, and intermembrane space

• Investigating Disease Mechanisms:

  • Analyze patient-derived cells carrying LYRM7 mutations

  • Compare LYRM7 and UQCRFS1 levels between patients and controls

  • Study complex III activity correlations with LYRM7 expression levels

• Complementation Assays:

  • Use lentiviral vectors expressing wild-type LYRM7 in patient cells

  • Assess restoration of complex III activity and assembly

  • Monitor UQCRFS1 stabilization upon LYRM7 complementation

Research has shown that LYRM7 mutations lead to reduced UQCRFS1 protein levels and impaired complex III assembly, resulting in mitochondrial dysfunction and clinical manifestations including leukoencephalopathy and encephalopathy .

What experimental designs are recommended for investigating LYRM7 interactions with the Rieske Fe-S protein?

To investigate LYRM7's chaperoning function for the Rieske Fe-S protein (UQCRFS1), consider these experimental approaches:

• Direct Protein-Protein Interaction Studies:

  • Co-immunoprecipitation with anti-LYRM7 or anti-UQCRFS1 antibodies

  • Proximity ligation assay to visualize in situ interactions

  • FRET or BiFC (Bimolecular Fluorescence Complementation) with fluorescently tagged proteins

  • Yeast two-hybrid screening to identify specific interaction domains

• Conditional Expression Systems:

  • Establish cell lines with inducible LYRM7 expression

  • Monitor UQCRFS1 stability upon LYRM7 induction/repression

  • Pulse-chase experiments to track UQCRFS1 turnover rates

• Mutational Analysis:

  • Generate LYRM7 constructs with mutations in the LYR motif

  • Test ability of mutants to bind and stabilize UQCRFS1

  • Create UQCRFS1 mutants to identify LYRM7 binding regions

  • Example: Studies have shown that the mutation p.Asp25Asn in LYRM7 disrupts its chaperone function

• Subcellular Fractionation:

  • Separate mitochondrial matrix from membrane fractions

  • Analyze distribution of LYRM7-UQCRFS1 complexes

  • Track changes in distribution upon complex III assembly perturbation

• In Vitro Reconstitution:

  • Express and purify recombinant LYRM7 and UQCRFS1

  • Perform binding assays under various conditions

  • Test effects of iron-sulfur cluster integrity on interaction

A comprehensive approach would involve multiple complementary techniques to build a complete picture of the LYRM7-UQCRFS1 interaction. Research has demonstrated that overexpression of LYRM7 can lead to altered UQCRFS1 submitochondrial distribution and impair complex III maturation, suggesting a delicate balance in this chaperone-client relationship .

How can LYRM7 antibodies be used to study mitochondrial disease mechanisms?

LYRM7 antibodies are valuable tools for investigating mitochondrial disease mechanisms, particularly those involving complex III deficiency:

• Patient Sample Analysis:

  • Compare LYRM7 protein levels in control vs. patient tissues/cells

  • Analyze correlation between LYRM7 levels and clinical severity

  • Assess effects of LYRM7 mutations on protein stability and localization

• Disease Modeling:

  • Create cellular disease models using CRISPR/Cas9 to introduce patient mutations

  • Use LYRM7 antibodies to verify mutant protein expression and localization

  • Analyze complex III assembly and function in these models

• Therapeutic Development Assessment:

  • Monitor LYRM7 expression/function during treatment trials

  • Use complementation assays to test gene therapy approaches

  • Example: Studies have used lentiviral vectors expressing wild-type LYRM7 to complement patient-derived cells

• Biomarker Development:

  • Assess LYRM7 levels in accessible tissues/fluids from patients

  • Correlate with disease progression or treatment response

  • Develop immunoassays for diagnostic applications

• Investigating Inflammatory Responses:

  • Recent research suggests TNF-α induced NF-κB regulates LYRM7 expression

  • Study how inflammatory signals affect mitochondrial function via LYRM7

  • This pathway appears relevant for breast cancer cell invasion and migration

Case studies have reported mutations in LYRM7 causing multifocal cavitating leukoencephalopathy, early-onset encephalopathy, and lactic acidosis . Using LYRM7 antibodies helps characterize the molecular defects underlying these clinical presentations.

What are the considerations for using LYRM7 antibodies in studies of non-mitochondrial disease states?

Recent research has expanded the relevance of LYRM7 beyond primary mitochondrial diseases:

• Cancer Research Applications:

  • TNF-α induced NF-κB has been identified as a critical regulator of LYRM7 expression

  • Downregulation of LYRM7 in breast cancer cells affects mitochondrial supercomplex assembly

  • This leads to increased ROS levels, enhancing invasion and migration potential

  • LYRM7 levels appear decreased in triple-negative breast cancer compared to other subtypes

  • Expression levels correlate with survival outcomes in patients

• Inflammatory Disease Contexts:

  • Study relationship between inflammatory cytokines and LYRM7 expression

  • Investigate effects of anti-inflammatory treatments on LYRM7 levels

  • Consider LYRM7 as a potential marker of inflammation-induced mitochondrial dysfunction

• Pulmonary Fibrosis Research:

  • LYRM7 has shown significant differential expression in pulmonary fibrosis models

  • Antibodies can be used to study LYRM7 expression in fibrotic lung tissue

  • Consider combined analysis with other markers like α-SMA

• Methodological Considerations:

  • Use tissue microarrays to assess LYRM7 expression across multiple disease states

  • Combine with markers of mitochondrial stress (e.g., oxidative damage markers)

  • Consider post-translational modifications that may affect antibody recognition

  • Control for factors affecting mitochondrial content (biogenesis, mitophagy)

• Experimental Design for Non-Mitochondrial Contexts:

  • Include appropriate tissue-specific controls

  • Consider cell-type specific expression patterns

  • Use multiple antibodies targeting different epitopes to confirm findings

  • Correlate protein expression with functional assays of mitochondrial activity

When using LYRM7 antibodies in these broader contexts, careful validation in the specific tissue/disease model is essential for reliable interpretation of results.

What are common pitfalls in LYRM7 antibody-based experiments and how can they be avoided?

Researchers commonly encounter these challenges when working with LYRM7 antibodies:

• Low Signal Intensity:

  • Cause: Low LYRM7 abundance in many cell types

  • Solution: Consider mitochondrial enrichment before analysis; use more sensitive detection methods; optimize antibody concentration; increase sample loading

• Non-specific Bands in Western Blots:

  • Cause: Cross-reactivity with other LYR-motif containing proteins

  • Solution: Use LYRM7 knockout/knockdown controls; validate band size (12 kDa); try alternative antibodies targeting different epitopes

• Inconsistent Results Between Experiments:

  • Cause: Variations in mitochondrial content or quality between samples

  • Solution: Normalize to mitochondrial markers (e.g., VDAC/porin); maintain consistent sample handling; standardize mitochondrial isolation procedures

• Poor Reproducibility in Immunostaining:

  • Cause: Variability in fixation affecting epitope accessibility

  • Solution: Standardize fixation protocols; optimize antigen retrieval methods (test both TE buffer pH 9.0 and citrate buffer pH 6.0)

• Difficulty Detecting Endogenous LYRM7:

  • Cause: Naturally low expression levels in many cell types

  • Solution: Choose appropriate positive control tissues (liver, kidney); consider using amplification systems for detection; ensure antibodies are sensitive enough for endogenous protein detection

How should I interpret conflicting results when using different LYRM7 antibodies?

When faced with conflicting results using different LYRM7 antibodies, consider this systematic approach:

• Epitope Mapping Analysis:

  • Determine which region of LYRM7 each antibody recognizes

  • Consider whether post-translational modifications might affect epitope accessibility

  • Check if alternative splicing of LYRM7 (e.g., LYRM7-001 vs LYRM7-003) might explain discrepancies

• Validation Strategy:

  • Test antibodies on positive and negative control samples (e.g., LYRM7 overexpression vs. knockout)

  • Compare reactivity patterns across multiple applications (WB, IHC, IF)

  • Consider peptide competition assays to confirm specificity

• Application-Specific Considerations:

  • Some antibodies may work well for Western blot but poorly for immunostaining due to epitope accessibility

  • Native vs. denatured protein recognition can vary between antibodies

  • Fixation methods may differentially affect epitope preservation

• Reconciliation Approaches:

  • Use multiple antibodies targeting different epitopes when possible

  • Consider the biological question - is one antibody more relevant for your specific research focus?

  • For critical findings, confirm with non-antibody-based methods (e.g., mass spectrometry, RNA analysis)

• Data Interpretation Guidelines:

  • Give more weight to results confirmed by multiple antibodies

  • Be transparent about antibody limitations in publications

  • Consider whether conflicting results might reveal biologically important information (e.g., presence of different isoforms or modified forms)

Research has shown that only the LYRM7-001 transcript produces a detectable protein product in some studies, despite LYRM7-003 being expressed at the mRNA level . This type of insight might help explain certain antibody discrepancies.

How can I analyze LYRM7 in the context of mitochondrial supercomplex organization?

Studying LYRM7 in relation to mitochondrial supercomplexes requires specialized techniques:

• Blue Native PAGE Analysis:

  • Digitonin-solubilized mitochondrial samples preserve supercomplex structures

  • Use mild detergent conditions (0.5-1% digitonin) to maintain native interactions

  • Perform 2D analysis (BN-PAGE followed by SDS-PAGE) to resolve supercomplex components

  • Immunoblot with anti-LYRM7 and subunits of complexes I, III, and IV

• Quantitative Analysis of Supercomplex Assembly:

  • Compare supercomplex profiles between normal and LYRM7-deficient samples

  • Measure relative abundance of free complex III vs. complex III in supercomplexes

  • Track assembly intermediates that accumulate in LYRM7 deficiency

  • Example finding: TNF-α induced downregulation of LYRM7 decreases mitochondrial supercomplex assembly

• Co-immunoprecipitation of Supercomplex Components:

  • Use antibodies against complex III components to pull down supercomplexes

  • Analyze presence of LYRM7 in these complexes

  • Study how LYRM7 mutations affect interactions with other supercomplex components

• Functional Correlation Studies:

  • Measure respiratory chain activities in relation to LYRM7 levels

  • Assess ROS production in LYRM7-deficient vs. normal cells

  • Correlate supercomplex stability with LYRM7 expression levels

  • Important finding: Decreased LYRM7 leads to increased ROS, which can enhance invasion and migration in cancer cells

• Alternative Electron Transfer Pathways:

  • Study how cells compensate for LYRM7/complex III deficiency

  • Investigate whether electron shunts (like pyocyanin) can bypass complex III defects

  • This approach has been explored for other complex III deficiencies

Research has shown that proper complex III assembly mediated by LYRM7 is essential not only for respiratory function but also for cellular processes beyond energy production, including cell migration and cancer progression .

What are the latest findings on LYRM7 function beyond mitochondrial complex III assembly?

Recent research has revealed several unexpected roles for LYRM7 beyond its classical function in complex III assembly:

• Inflammatory Signaling Crosstalk:

  • TNF-α induced NF-κB has been identified as a regulator of LYRM7 expression

  • This represents a novel link between inflammatory signaling and mitochondrial function

  • LYRM7 downregulation increases ROS levels, potentially contributing to inflammation-related pathologies

• Cancer Biology Connections:

  • LYRM7 levels are decreased in triple-negative breast cancer compared to other subtypes

  • Expression levels correlate with patient survival outcomes

  • LYRM7 appears to influence cancer cell invasion and migration through ROS-dependent mechanisms

  • Targeting this pathway might represent a novel therapeutic approach

• Pulmonary Fibrosis Implications:

  • LYRM7 shows significant differential expression in pulmonary fibrosis models

  • It may be part of a "cuproptosis score" with prognostic significance

  • Relationships with TGF-β signaling suggest a role in fibrotic processes

• Mitochondrial Acyl-Carrier Protein Interaction Network:

  • LYRM7 has been identified in the mitochondrial acyl-carrier protein (NDUFAB1) interaction network

  • This suggests potential involvement in mitochondrial fatty acid synthesis or other metabolic pathways

  • Understanding these interactions may reveal new functions for LYRM7

• Therapeutic Targeting Potential:

  • Studies with TNF-α inhibitors (e.g., Infliximab) have shown effects on LYRM7 expression

  • This suggests potential therapeutic approaches targeting LYRM7 regulation

  • Further research is needed to fully understand the clinical implications

These findings suggest LYRM7 functions at the intersection of mitochondrial bioenergetics, inflammatory signaling, and cellular stress responses, opening new avenues for investigation.

What novel techniques are advancing LYRM7 research?

Several cutting-edge methodologies are enhancing our understanding of LYRM7 biology:

• Proximity Labeling Proteomics:

  • BioID and TurboID approaches can identify proteins in close proximity to LYRM7

  • These techniques have revealed novel interaction partners beyond the known UQCRFS1 association

  • Example: BioID analysis has been used to study the mitochondrial acyl-carrier protein interaction network including LYRM7

• Cryo-Electron Microscopy:

  • High-resolution structural studies of complex III assembly intermediates

  • Potential to visualize LYRM7-UQCRFS1 interactions at molecular level

  • May reveal conformational changes during the chaperone-client relationship

• CRISPR-Based Screening:

  • Genome-wide CRISPR screens to identify synthetic lethal interactions with LYRM7 deficiency

  • CRISPR activation/interference to study LYRM7 regulation

  • Base editing approaches for precise modeling of patient mutations

• Live-Cell Imaging Techniques:

  • FRET-based sensors to monitor LYRM7-UQCRFS1 interactions in real-time

  • Photo-convertible fluorescent tags to track LYRM7 dynamics

  • Super-resolution microscopy to visualize submitochondrial localization

• Integrative Multi-Omics Approaches:

  • Combining proteomics, transcriptomics, and metabolomics to understand LYRM7 function

  • Network analysis to position LYRM7 in broader cellular pathways

  • Example: Studies have integrated patient genetic data with functional assays and protein analysis to characterize LYRM7-related diseases

These advanced techniques are providing unprecedented insights into LYRM7 function and regulation, potentially leading to new therapeutic strategies for mitochondrial disorders and other conditions where LYRM7 plays a role.

What considerations are important when designing LYRM7 antibody-based experiments for translational research?

When designing LYRM7 antibody-based experiments with translational potential, researchers should consider:

• Biospecimen Selection and Handling:

  • LYRM7 expression varies across tissues - liver, kidney, and testis show positive immunoreactivity

  • Standardize collection and preservation methods to maintain epitope integrity

  • Consider accessibility of tissue for clinical translation (e.g., blood cells vs. muscle biopsy)

• Quantification Methods for Clinical Correlation:

  • Develop standardized scoring systems for LYRM7 immunostaining

  • Consider digital pathology approaches for objective quantification

  • Correlate with functional mitochondrial assays and clinical parameters

• Multicenter Validation Considerations:

  • Use commercially available antibodies with consistent lot-to-lot performance

  • Implement standard operating procedures for sample processing

  • Develop reference materials for inter-laboratory calibration

  • Consider antibody validation strategies as recommended by International Working Group for Antibody Validation

• Patient Stratification Approaches:

  • Determine if LYRM7 levels or localization patterns can distinguish patient subgroups

  • Correlate with clinical outcomes and treatment responses

  • Example: LYRM7 levels might have prognostic significance in cancer patients

• Companion Diagnostic Development:

  • Assess feasibility of LYRM7 antibody-based assays as companion diagnostics

  • Determine sensitivity and specificity in relevant clinical contexts

  • Consider regulatory requirements for diagnostic development

• Targeted Therapy Monitoring:

  • Develop assays to monitor LYRM7 expression/function during treatment

  • Assess whether LYRM7 can serve as a pharmacodynamic biomarker

  • Example: TNF-α inhibitors like Infliximab have shown effects on LYRM7 expression

By addressing these considerations, researchers can enhance the translational impact of LYRM7 antibody-based research and potentially develop clinically relevant applications.